Opus Genetics (IRD) Accumulated Expenses (2019 - 2026)

Opus Genetics (IRD) has 8 years of Accumulated Expenses data on file, last reported at $4.9 million in Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 854.95% year-over-year to $4.9 million in Q1 2026; TTM through Mar 2026 was $4.9 million, a 854.95% increase from a year earlier, with the FY2025 full-year figure at $4.5 million, down 44.91% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $4.9 million, up from $4.5 million in the prior quarter.
• Over the last five years, Accumulated Expenses for IRD reached as high as $8.1 million in Q4 2024 and fell as low as $233000.0 in Q1 2023.
• Historically, Accumulated Expenses has averaged $2.5 million across 5 years, with a median of $1.4 million in 2022.
• Across the five-year window, Accumulated Expenses surged 1466.09% in 2024 and tumbled 85.89% in 2025, its largest moves.
• Year by year, Accumulated Expenses stood at $782000.0 in 2022, then dropped by 3.71% to $753000.0 in 2023, then jumped by 981.94% to $8.1 million in 2024, then slumped by 44.91% to $4.5 million in 2025, then advanced by 9.58% to $4.9 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $4.9 million in Q1 2026, $4.5 million in Q4 2025, and $1.4 million in Q3 2025.